Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma. It has a license and stock issuance agreement with Forendo Pharma Ltd. to develop and commercialize fispemifene, a tissue-specific selective estrogen receptor modulator to treat symptomatic secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men. Apricus Biosciences, Inc. operates in Europe, Canada, Latin America, and the Asia Pacific. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APRI
Previous Symbol
CUSIPN/A
Phone858-222-8041
Debt
Debt-to-Equity RatioN/A
Current Ratio3.86
Quick Ratio3.86
Price-To-Earnings
Trailing P/E Ratio-0.23
Forward P/E Ratio-0.58
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.76 million
Price / Sales1.12
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.29 per share
Price / Book0.79
Profitability
EPS (Most Recent Fiscal Year)($0.99)
Net Income$320,000.00
Net MarginsN/A
Return on Equity-216.45%
Return on Assets-153.13%
Miscellaneous
Employees11
Outstanding Shares28,170,000
Market Cap$7.90 million
OptionableNot Optionable
Apricus Biosciences (NASDAQ:APRI) Frequently Asked Questions
What is Apricus Biosciences' stock symbol?
Apricus Biosciences trades on the NASDAQ under the ticker symbol "APRI."
How were Apricus Biosciences' earnings last quarter?
Apricus Biosciences Inc (NASDAQ:APRI) issued its earnings results on Wednesday, October, 31st. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. View Apricus Biosciences' Earnings History.
When is Apricus Biosciences' next earnings date?
What price target have analysts set for APRI?
1 brokers have issued 1 year price targets for Apricus Biosciences' stock. Their predictions range from $1.00 to $1.00. On average, they expect Apricus Biosciences' stock price to reach $1.00 in the next year. This suggests a possible upside of 334.8% from the stock's current price. View Analyst Price Targets for Apricus Biosciences.
What is the consensus analysts' recommendation for Apricus Biosciences?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apricus Biosciences in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Apricus Biosciences.
Has Apricus Biosciences been receiving favorable news coverage?
News stories about APRI stock have been trending somewhat positive on Tuesday, InfoTrie reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Apricus Biosciences earned a media sentiment score of 1.9 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term.
Who are some of Apricus Biosciences' key competitors?
Some companies that are related to Apricus Biosciences include Oncomed Pharmaceuticals (OMED), Heat Biologics (HTBX), VIVUS (VVUS), Lipocine (LPCN), AzurRx BioPharma (AZRX), GTX (GTXI), Novus Therapeutics (NVUS), DiaMedica Therapeutics (DMAC), Sernova (SEOVF), Trillium Therapeutics (TRIL), Akari Therapeutics (AKTX), IMMURON LTD/S (IMRN), Agile Therapeutics (AGRX), Millendo Therapeutics (MLND) and Adial Pharmaceuticals (ADIL).
Who are Apricus Biosciences' key executives?
Apricus Biosciences' management team includes the folowing people:
- Mr. Richard W. Pascoe, CEO, CFO, Sec., Principal Accounting Officer & Director (Age 54)
- Mr. Neil C. Morton, Sr. VP & Chief Bus. Officer (Age 42)
- Mr. Brian T. Dorsey, Consultant (Age 49)
- Ms. Kelly Deck, Exec. Director of Fin.
- Ms. Mary Naggs, VP & Gen. Counsel
Who are Apricus Biosciences' major shareholders?
Which major investors are selling Apricus Biosciences stock?
How do I buy shares of Apricus Biosciences?
Shares of APRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Apricus Biosciences' stock price today?
One share of APRI stock can currently be purchased for approximately $0.23.
How big of a company is Apricus Biosciences?
Apricus Biosciences has a market capitalization of $7.90 million and generates $5.76 million in revenue each year. The company earns $320,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. Apricus Biosciences employs 11 workers across the globe.
What is Apricus Biosciences' official website?
How can I contact Apricus Biosciences?
Apricus Biosciences' mailing address is 11975 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company can be reached via phone at 858-222-8041 or via email at [email protected]
MarketBeat Community Rating for Apricus Biosciences (NASDAQ APRI)
MarketBeat's community ratings are surveys of what our community members think about Apricus Biosciences and other stocks. Vote "Outperform" if you believe APRI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APRI will underperform the S&P 500 over the long term. You may vote once every thirty days.
